On July 6, Hansoh Pharma rose 3.74% in regular trading, trading at HKD 34.98/share, with turnover of HKD 292 million.
The rally extends gains from recent pipeline catalysts. On July 2, the company announced that its self-developed Class 1 new drug HS-20136-2 injection received two clinical trial approvals from China's NMPA for type 2 diabetes mellitus and weight management indications. The approval marks a differentiated entry into the metabolic disease space, with no similar product currently approved domestically.
The clinical trial greenlight adds to a dense wave of catalysts including the NDA acceptance of GLP-1/GIP dual agonist Olepeptide for weight management, the NDA acceptance of HS-10568 injection for secondary hyperparathyroidism, and the recent registration certificate for Pemosarfide injection. Multiple brokerages maintain Buy ratings with target prices in the HKD 40-46 range.
The broader pharmaceuticals sector is rallying concurrently, with CSPC Pharma up 6.12%, SBP Group up 10.97%, Hengrui Pharma up 3.92%, and Haixi Pharma up 10.23%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
